Oh, D., Kang, Y., Shitara, K., Chen, L., Boku, N., Ryu, M., Rha, S. Y., Kim, J. G., Kim, J. Y., Oh, S. C., Lee, K., Lee, J., Kawazoe, A., Shoji, H., Yamaguchi, K., Oh, S. Y., Bai, L., Chen, M., Chen, J., Yeh, K. (2026). Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: A randomized phase 3 trial (ATTRACTION-6).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4006